
AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing
AstraZeneca is establishing a new global strategic R&D centre in Beijing, its second in China and sixth worldwide Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai Press Release – 21 March 2025 – AstraZeneca today announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre together with major research and manufacturing agreements that will further advance … Continue reading AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing